TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Feb, 27, 2023
I think that's a good number considering all t... See more
Feb, 27, 2023
Super excited for tomorrow's ER Guidance Call ... See more
AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Jan, 13, 2023
They have a great product treating cancer with imm... See more
Jan, 6, 2023
look into Adamis Pharma, no more speculation, now ... See more
XERS
Xeris Biopharma Holdings Inc
15.52%
$1.16 - $1.34
Feb 7th 2023 - Mar 21st 2023
Mar, 17, 2023
$XERS their primary product increases 9% week to w... See more
Mar, 14, 2023
$XERS I like their products and the inject opportu... See more
Feb, 27, 2023
I think that's a good number considering all the work that goes into launching a product.
Feb, 27, 2023
Super excited for tomorrow's ER Guidance Call for our first ever FDA approved commercialized product, Briumvi!
Feb, 4, 2023
It’s not just the efficacy and safety of the product, it is the less cost for hospital/infusion, due to one hour infusion and the huge difference in price.
Jan, 4, 2023
Imagine how much Ubli could be worth to BP now with Briumvi’s best in class product profile.
Dec, 30, 2022
$TGTX This gonna be amazing guys after they sell their product Lets say 50.000 usd for the dose and they sell 500 a month Make the math and tell me how revenue they will get every quarter
Dec, 30, 2022
This is not some get rich scheme, this is a solid biotech company with an approved product that will bring in billions in revenue.
Jan, 13, 2023
They have a great product treating cancer with immunotherapy, peer reviewed journal
Jan, 6, 2023
look into Adamis Pharma, no more speculation, now it's real, two FDA approved meds, two major products, top of the line in comparison of their rivals, for cheaper price, AND WITH NO MUCH COMPETITION!
Dec, 14, 2022
2023 is going to be very positive for patients of our products and shareholders alike
Dec, 6, 2022
Their product works (see the mad Pole Piotr’s graphs 😵💫) Multi year holds, the bodadem.
Dec, 5, 2022
We have great data out of a superior product,
Oct, 18, 2022
They have good products and a solid future.
Mar, 17, 2023
$XERS their primary product increases 9% week to week sales with an overall trend that's incredible.
Mar, 14, 2023
$XERS I like their products and the inject opportunity with Horizon Tepezza is huge I wish they weren't acquired so they can keep a focus on that.
Jan, 23, 2023
Earnings are growing and there could be great news any day from a variety of sources, whether a collab exercise of option, new product collab, royalty pmt, etc.
Jan, 5, 2023
More important is that they grow Recorlev's revenue at high(er) speed, and continue to gain market share with Gvoke without product price drop.
Jan, 1, 2023
Revenue exploding on the upside with their 4 products.
Dec, 23, 2022
Even if they have more short term gains coming soon, we know the Gvoke product will gain share back due to the more pleasant experience. Patience.
Dec, 23, 2022
Gvoke is the best and easiest product out there.
Dec, 13, 2022
Products have been approved and much more is coming, wait and relax.
Nov, 4, 2022
For a tiny company like xeris to go toe to toe with lilly and grow share shows they have the best product.
Nov, 2, 2022
$XERS Truly so strange, everything Xeris had in its programme has been met, briefly 3 FDA approved products, collaborations with major pharmacies and much, much more.